Epidermal growth factor receptor mutations in lung cancer

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338

EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

Druker, B. J., Tamura, S., Buchdunger, E., Ohno-Jones, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 3,652

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527

ERBB receptors and cancer: the complexity of targeted inhibitors

Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379

The Consensus Coding Sequences of Human Breast and Colorectal Cancers

Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161

Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104

PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)

He, M., Cao, C., Ni, Z., Liu, Y., Song, P., Hao, S., He, Y., Sun, X., & Rao, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00999-9 · Cited by 283

Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop

Pirker, R., Herth, F. J. F., Kerr, K. M., Filipits, M., Tarón, M., Gandara, D. R., Hirsch, F. R., Grunenwald, D. H., Popper, H., Smit, E. F., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f1c8de · Cited by 283

Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer

Franovic, A., Gunaratnam, L., Smith, K., Robert, I., Patten, D., & Lee, S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702387104 · Cited by 250

Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance

Schwartz, P. A., Kuzmic, P., Solowiej, J., Bergqvist, S., Bolanos, B., Almaden, C., Nagata, A., Ryan, K., Feng, J., Dalvie, D., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313733111 · Cited by 281

Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches

Dietlein, F., Thelen, L., & Reinhardt, H. C. (2014) · Trends in Genetics · doi:10.1016/j.tig.2014.06.003 · Cited by 290

Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer

Brugger, W., Triller, N., Błasińska-Morawiec, M., Curescu, S., Sakalauskas, R., Manikhas, G. M., Mazières, J., Whittom, R., Ward, C., Mayne, K., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8162 · Cited by 284

Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)

Ward, R. A., Anderton, M. J., Ashton, S., Bethel, P. A., Box, M., Butterworth, S., Colclough, N., Chorley, C. G., Chuaqui, C., Cross, D. A. E., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400822z · Cited by 279

The molecular pathology of cancer

Harris, T., & McCormick, F. P. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.41 · Cited by 286

Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis

Melosky, B. L., Kambartel, K.-O., Häntschel, M., Bennetts, M., Nickens, D. J., Brinkmann, J., Kayser, A., Moran, M., & Cappuzzo, F. (2021) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-021-00563-1 · Cited by 287

Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology

Mithoowani, H., & Febbraro, M. (2022) · Current Oncology · doi:10.3390/curroncol29030150 · Cited by 281

Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers

Reimand, J., & Bader, G. D. (2013) · Molecular Systems Biology · doi:10.1038/msb.2012.68 · Cited by 274

Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses

Yang, X., Zhang, X., Fu, M. L., Weichselbaum, R. R., Gajewski, T. F., Guo, Y., & Fu, Y. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.004 · Cited by 274

Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins

Pance, K., Gramespacher, J. A., Byrnes, J. R., Salangsang, F., Serrano, J.-A. C., Cotton, A. D., Steri, V., & Wells, J. A. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01456-2 · Cited by 265

Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer

Cai, X., Zhai, H.-X., Wang, J., Forrester, J. S., Qu, H., Yin, L., Lai, C.-J., Bao, R., & Qian, C. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901453q · Cited by 264

Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer

Aissa, A. F., Islam, A. B. M. M. K., Ariss, M., Go, C. C., Rader, A. E., Conrardy, R. D., Gajda, A. M., Rubio-Pérez, C., Valyi‐Nagy, K., Pasquinelli, M. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21884-z · Cited by 278

EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases

Schmid, K., Oehl, N., Wrba, F., Pirker, R., Pirker, C., & Filipits, M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0089 · Cited by 261

Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants

Heuckmann, J. M., Balke‐Want, H., Malchers, F., Peifer, M., Sos, M. L., Koker, M., Meder, L., Lovly, C. M., Heukamp, L. C., Pao, W. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3260 · Cited by 261

Lung Cancer Biomarkers

Villalobos, P. A., & Wistuba, I. I. (2016) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2016.08.006 · Cited by 268

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer

Sos, M. L., Fischer, S., Ullrich, R. T., Peifer, M., Heuckmann, J. M., Koker, M., Heynck, S., Stückrath, I., Weiss, J. M., Fischer, F., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907325106 · Cited by 258

Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions

Sos, M. L., Michel, K., Zander, T., Weiss, J. M., Frommolt, P., Peifer, M., Li, D., Ullrich, R. T., Koker, M., Fischer, F., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37127 · Cited by 258

Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease

Hoffknecht, P., Tufman, A., Wehler, T., Pelzer, T., Wiewrodt, R. G., Schütz, M., Serke, M. H., Stöhlmacher-Williams, J., Märten, A., Huber, R. M., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000380 · Cited by 259

Tumor Targeting Strategies of Smart Fluorescent Nanoparticles and Their Applications in Cancer Diagnosis and Treatment

He, J., Li, C., Ding, L., Huang, Y., Yin, X., Zhang, J., Zhang, J., Yao, C., Liang, M., Pirraco, R. P., et al. (2019) · Advanced Materials · doi:10.1002/adma.201902409 · Cited by 248

Mitochondrial signaling in cell death via the Bcl-2 family

Leibowitz, B. J., & Yu, J. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.6.11392 · Cited by 250

Molecular pathology of lung cancer: key to personalized medicine

Liang Cheng, C., Alexander, R. E., MacLennan, G. T., Cummings, O. W., Montironi, R., Antonio Lopez-beltran, B., Cramer, H. M., Davidson, D. D., & Zhang, S. (2012) · Modern Pathology · doi:10.1038/modpathol.2011.215 · Cited by 249

KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer

Alam, H., Tang, M., Maitituoheti, M., Dhar, S. S., Kumar, M., Han, C. Y., Ambati, C. R., Amin, S. B., Gu, B., Chen, T.-Y., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.005 · Cited by 243

Cancer Biomarkers: Are We Ready for the Prime Time?

Mishra, A., & Verma, M. (2010) · Cancers · doi:10.3390/cancers2010190 · Cited by 255

The Role of EREG/EGFR Pathway in Tumor Progression

Cheng, W., Feng, P., Lee, K., Chen, K.-Y., Sun, W.-L., Hiệp, N. V., Luo, C.-S., & Wu, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312828 · Cited by 246

MYC in Oncogenesis and as a Target for Cancer Therapies

Albihn, A., Johnsen, J. I., & Arsenian‐Henriksson, M. (2010) · Advances in cancer research · doi:10.1016/s0065-230x(10)07006-5 · Cited by 246

Lung Cancer Cell Lines as Tools for Biomedical Discovery and Research

Gazdar, A. F., Girard, L., Lockwood, W. W., Lam, W. L., & Minna, J. D. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq279 · Cited by 240

Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation negatively modulates EGFR-mediated ERK activation

Hsu, J.-M., Chen, C., Chou, C., Kuo, H.-P., Li, L., Lin, C.-Y., Lee, H.-J., Wang, Y., Liu, M., Liao, H.-W., et al. (2011) · Nature Cell Biology · doi:10.1038/ncb2158 · Cited by 244

Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma

Bresler, S. C., Wood, A., Haglund, E. A., Courtright, J., Belcastro, L. T., Plegaria, J. S., Cole, K. A., Toporovskaya, Y., Zhao, H., Carpenter, E. L., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002950 · Cited by 242

Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy

Rodak, O., Peris‐Díaz, M. D., Olbromski, M., Podhorska‐Okołów, M., & Dzięgiel, P. (2021) · Cancers · doi:10.3390/cancers13184705 · Cited by 250

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC

Linardou, H., Dahabreh, I. J., Bafaloukos, D. I., Kosmidis, P., & Murray, S. J. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.62 · Cited by 236

Cell Type Variation in Responses to Antimitotic Drugs that Target Microtubules and Kinesin-5

Shi, J., Orth, J. D., & Mitchison, T. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6699 · Cited by 235

An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors

Chitale, D. A., Gong, Y., Taylor, B. S., Broderick, S., Brennan, C., Somwar, R., Golas, B., Wang, L., Motoi, N., Szőke, J., et al. (2009) · Oncogene · doi:10.1038/onc.2009.135 · Cited by 232

Chromosomal Abnormalities in Cancer

Fröhling, S., & Döhner, H. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0803109 · Cited by 229

Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer

Eck, M. J., & Yun, C.-H. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.12.010 · Cited by 225

Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation.

Sos, M. L., Rode, H. B., Heynck, S., Peifer, M., Fischer, F., Klüter, S., Pawar, V. G., Reuter, C., Heuckmann, J. M., Weiss, J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3106 · Cited by 220

Molecular pathways and therapeutic targets in lung cancer

Shtivelman, E., Hensing, T., Simon, G. R., Dennis, P. A., Otterson, G. A., Bueno, R., & Salgia, R. (2014) · Oncotarget · doi:10.18632/oncotarget.1891 · Cited by 220

EGFR and NF-κB: partners in cancer

Shostak, K., & Chariot, A. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.04.001 · Cited by 222

Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2

Foster, S. A., Whalen, D. M., Özen, A., Wongchenko, M. J., Yin, J., Yen, I., Schaefer, G., Mayfield, J. D., Chmielecki, J., Stephens, P. J., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.010 · Cited by 217

High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer

Clarke, J. L., Pao, W., Wu, N., Miller, V. A., & Lassman, A. B. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0128-6 · Cited by 214

CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity

Lai, C.-J., Bao, R., Tao, X., Wang, J., Atoyan, R., Qu, H., Wang, D.-G., Yin, L., Samson, M., Forrester, J. S., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3360 · Cited by 217

Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy

Song, X., Liu, C., Wang, N., Huang, H., He, S., Gong, C., & Wei, Y. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.04.010 · Cited by 217

Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis

Luo, J., Shen, L., & Zheng, D. (2014) · Scientific Reports · doi:10.1038/srep06269 · Cited by 212

Pathogenesis of lung cancer signalling pathways: roadmap for therapies

Brambilla, E. M., & Gazdar, A. F. (2009) · European Respiratory Journal · doi:10.1183/09031936.00014009 · Cited by 223

Toward understanding the selective anticancer capacity of cold atmospheric plasma—A model based on aquaporins (Review)

Yan, D., Talbot, A., Nourmohammadi, N., Sherman, J. H., Cheng, X., & Keidar, M. (2015) · Biointerphases · doi:10.1116/1.4938020 · Cited by 214

An analysis of genetic heterogeneity in untreated cancers

Reiter, J. G., Baretti, M., Gerold, J. M., Makohon-Moore, A. P., DAUD, A. I., Iacobuzio–Donahue, C. A., Azad, N. S., Kinzler, K. W., Nowak, M. A., & Vogelstein, B. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0185-x · Cited by 213

Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)

Hsu, P., Jablons, D. M., Yang, C., & You, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153821 · Cited by 215

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib

Wind, S., Schnell, D., Ebner, T., Freiwald, M., & Stopfer, P. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0440-1 · Cited by 206

Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors

John, T., Liu, G., & Tsao, M. (2009) · Oncogene · doi:10.1038/onc.2009.197 · Cited by 211

EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research

Dong, R., Zhu, M., Liu, M., Xu, Y., Yuan, L.-L., Bian, J., Xia, Y., & Kong, L. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105583 · Cited by 211

Assessment of EGFR Mutation Status in Lung Adenocarcinoma by Immunohistochemistry Using Antibodies Specific to the Two Major Forms of Mutant EGFR

Brevet, M., Arcila, M. E., & Ladanyi, M. (2010) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2010.090140 · Cited by 205

Insights into the Aberrant Activity of Mutant EGFR Kinase Domain and Drug Recognition

Gajiwala, K. S., Feng, J., Ferre, R. A., Ryan, K., Brodsky, O., Weinrich, S. L., Kath, J. C., & Stewart, A. (2012) · Structure · doi:10.1016/j.str.2012.11.014 · Cited by 204

EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer

Wang, S., Tsui, S. T., Liu, C., Song, Y., & Liu, D. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0290-1 · Cited by 208

Rethink of EGFR in Cancer With Its Kinase Independent Function on Board

Thomas, R., & Weihua, Z. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00800 · Cited by 215

CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation

Kashima, K., Kawauchi, H., Tanimura, H., Tachibana, Y., Chiba, T., Torizawa, T., & Sakamoto, H. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0229 · Cited by 208

Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC

Kalikaki, A., Koutsopoulos, A. V., Trypaki, M., Souglakos, J., Stathopoulos, E. N., Georgoulias, V., Mavroudis, D., & Voutsina, A. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604629 · Cited by 204

N‐myc downstream regulated gene 1 modulates Wnt‐β‐catenin signalling and pleiotropically suppresses metastasis

Liu, W., Xing, F., Iiizumi‐Gairani, M., Okuda, H., Watabe, M., Pai, S. K., Pandey, P. R., Hirota, S., Kobayashi, A., Mo, Y., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201100190 · Cited by 190

Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The “Rotation Model”

Purba, E. R., Saita, E., & MARUYAMA, I. N. (2017) · Cells · doi:10.3390/cells6020013 · Cited by 218

A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers

Hanada, K.-I., Zhao, C., Gil-Hoyos, R., Gartner, J. J., Chow-Parmer, C., Lowery, F. J., Krishna, S., Prickett, T. D., Kivitz, S., Parkhurst, M. R., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.03.012 · Cited by 200

Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell Lines

Gandhi, J., Zhang, J., Xie, Y., Soh, J., Shigematsu, H., Zhang, W., Yamamoto, H., Peyton, M., Girard, L., Lockwood, W. W., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004576 · Cited by 200

Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer

de Bruin, E. C., Cowell, C., Warne, P. H., Jiang, M. Z., Saunders, R. E., Melnick, M. A., Gettinger, S. N., Walther, Z., Wurtz, A., Heynen, G. J. J. E., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0741 · Cited by 201

Ligand-Independent EGFR Signaling

Guo, G., Gong, K., Wohlfeld, B., Hatanpaa, K. J., Zhao, D., & Habib, A. A. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0989 · Cited by 205

EGFR-mutated lung cancer: a paradigm of molecular oncology

Zhang, Z., Stiegler, A. L., Boggon, T. J., Kobayashi, S., & Halmos, B. (2010) · Oncotarget · doi:10.18632/oncotarget.186 · Cited by 197

Treatment of Stage IV Non-small Cell Lung Cancer

Socinski, M. A., Evans, T. L., Gettinger, S. N., Hensing, T. A., Sequist, L. V. D., Ireland, B. K., & Stinchcombe, T. E. (2013) · CHEST Journal · doi:10.1378/chest.12-2361 · Cited by 206

Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders

Cheng, M., Yu, X., Lu, K. J., Xie, L., Wang, L., Meng, F., Han, X., Chen, X., Liu, J., Xiong, Y., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01566 · Cited by 197

Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype

Zheng, F.-M., Yue, C., Li, G., He, B., Cheng, W., Wang, X., Yan, M., Long, Z., Qiu, W., Yuan, Z., et al. (2016) · Nature Communications · doi:10.1038/ncomms10180 · Cited by 196

Peptide Targeted Lipid Nanoparticles for Anticancer Drug Delivery

Pearce, T. R., Shroff, K., & Kokkoli, E. (2012) · Advanced Materials · doi:10.1002/adma.201200832 · Cited by 198

Targeted therapies for treatment of non‐small cell lung cancer—Recent advances and future perspectives

Minguet, J., Smith, K. H., & Bramlage, P. (2015) · International Journal of Cancer · doi:10.1002/ijc.29915 · Cited by 198

Early detection of lung cancer biomarkers through biosensor technology: A review

Roointan, A., Mir, T. A., Wani, S. I., Mati-ur-Rehman, Hussain, K. K., Ahmed, B., Abrahim, S., Savardashtaki, A., Gandomani, G., Gandomani, M., et al. (2018) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2018.10.017 · Cited by 198

Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance

Santoni‐Rugiu, E., Melchior, L. C., Urbanska, E. M., Jakobsen, J. N., de Stricker, K., Grauslund, M., & Sørensen, J. B. (2019) · Cancers · doi:10.3390/cancers11070923 · Cited by 202

Emergence of Epidermal Growth Factor Receptor T790M Mutation during Chronic Exposure to Gefitinib in a Non–Small Cell Lung Cancer Cell Line

Ogino, A., Kitao, H., Hirano, S., Uchida, A., Ishiai, M., Kozuki, T., Takigawa, N., Takata, M., Kiura, K., & Tanimoto, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0681 · Cited by 194

KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling

Wagner, K. W., Alam, H., Dhar, S. S., Giri, U. P., Li, N., Wei, Y., Giri, D., Cascone, T., Kim, J.-H., Ye, Y., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68642 · Cited by 196

Epidermal growth factor receptor is a preferred target for treating Amyloid-β–induced memory loss

Wang, L., Chiang, H.-C., Wu, W., Liang, B., Xie, Z., Yao, X., Ma, W., Du, S., & Zhong, Y. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208011109 · Cited by 190

Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer

Gonzalvez, F., Vincent, S., Baker, T. E., Gould, A. E., Li, S., Wardwell, S. D., Nadworny, S., Ning, Y., Zhang, S., Huang, W.-S., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1683 · Cited by 190

Circulating Tumor DNA Is Effective for the Detection of EGFR Mutation in Non–Small Cell Lung Cancer: A Meta-analysis

Qiu, M., Wang, J., Xu, Y., Ding, X., Li, M., Jiang, F., Xu, L., & Yin, R. H. (2014) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0895 · Cited by 193

Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer

Tang, Z., Du, R., Jiang, S., Wu, C., Barkauskas, D. S., Richey, J. S., Molter, J. P., Lam, M., Flask, C. A., Gerson, S. L., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604559 · Cited by 188

Mechanisms of drug resistance in kinases

Barouch‐Bentov, R., & Sauer, K. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.546344 · Cited by 192

Lung cancer in never smokers: Disease characteristics and risk factors

Pallis, A. G., & Syrigos, K. N. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.06.011 · Cited by 183

Structural Basis for Negative Cooperativity in Growth Factor Binding to an EGF Receptor

Alvarado, D., Klein, D. E., & Lemmon, M. A. (2010) · Cell · doi:10.1016/j.cell.2010.07.015 · Cited by 181

New wirings in the survivin networks

Altieri, D. C. (2008) · Oncogene · doi:10.1038/onc.2008.303 · Cited by 181

Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors

Nukaga, S., Yasuda, H., Tsuchihara, K., Hamamoto, J., Masuzawa, K., Kawada, I., Naoki, K., Matsumoto, S., Mimaki, S., Ikemura, S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2359 · Cited by 182

Recognition of subtype non-small cell lung cancer by DNA aptamers selected from living cells

Zhao, Z., Xu, L., Shi, X., Tan, W., Fang, X., & Shangguan, D. (2009) · The Analyst · doi:10.1039/b904476k · Cited by 178

Noninvasive Saliva-based EGFR Gene Mutation Detection in Patients with Lung Cancer

Wei, F., Lin, C., Joon, A. Y., Feng, Z., Troche, G. E., Lira, M. E., Chia, D., Mao, M., Ho, C., Su, W., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201406-1003oc · Cited by 180

Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non–Small-Cell Lung Cancer: A Clash of the Generations

Shah, R. N. H., & Lester, J. F. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.12.003 · Cited by 183

Mutational spectra of human cancer

Pfeifer, G. P., & Nia, A. B. (2009) · Human Genetics · doi:10.1007/s00439-009-0657-2 · Cited by 180

Phosphoproteomics in cancer

Gowda, H., & Pandey, A. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.09.004 · Cited by 177

Inhibition of Hsp90 Down-regulates Mutant Epidermal Growth Factor Receptor (EGFR) Expression and Sensitizes EGFR Mutant Tumors to Paclitaxel

Sawai, A., Chandarlapaty, S., Greulich, H. E., Gönen, M., Ye, Q., Arteaga, C. L., Sellers, W. R., Rosen, N. X., & Solit, D. B. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-1570 · Cited by 179

Personalized Medicine and Inhibition ofEGFRSignaling in Lung Cancer

Gazdar, A. F. (2009) · New England Journal of Medicine · doi:10.1056/nejme0905763 · Cited by 177

Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor

Mallon, R. G., Feldberg, L. R., Lucas, J., Chaudhary, I., Dehnhardt, C. M., Santos, E. D., Chen, Z., dos Santos, O., Ayral‐Kaloustian, S., Venkatesan, A. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1694 · Cited by 181

Developing c-MET pathway inhibitors for cancer therapy: progress and challenges

Liu, X., Newton, R. C., & Scherle, P. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.11.005 · Cited by 176

Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS

Korpanty, G. J., Graham, D. M., Vincent, M. D., & Leighl, N. B. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00204 · Cited by 179

Does your gene need a background check? How genetic background impacts the analysis of mutations, genes, and evolution

Chandler, C. H., Chari, S., & Dworkin, I. M. (2013) · Trends in Genetics · doi:10.1016/j.tig.2013.01.009 · Cited by 182

Targeting EGFR L858R/T790M and EGFR L858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry

Lu, X., Yu, L., Zhang, Z., Ren, X., Smaill, J. B., & Ding, K. (2018) · Medicinal Research Reviews · doi:10.1002/med.21488 · Cited by 173

A Personalized Approach to Cancer Treatment: How Biomarkers Can Help

Duffy, M. J., & Crown, J. P. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.110056 · Cited by 176

Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib

Costa, D. B., Nguyen, K.-S. H., Cho, B. C., Sequist, L. V., Jackman, D. M., Riely, G. J., Yeap, B. Y., Halmos, B., Kim, J. H., Jänne, P. A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1455 · Cited by 171

The Use of Genomics in Clinical Trial Design

Simon, R. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4531 · Cited by 171

Functional Analysis of Epidermal Growth Factor Receptor (EGFR) Mutations and Potential Implications for EGFR Targeted Therapy

Kancha, R. K., von Bubnoff, N., Peschel, C., & Duyster, J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1757 · Cited by 168

Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer

Chen, L., Fu, W., Zheng, L., Liu, Z., & Liang, G. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01310 · Cited by 169

Epidermal Growth Factor Receptor Mutations

McLoughlin, E. M., & Gentzler, R. D. (2020) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2020.01.008 · Cited by 23

Molecular Targeted Therapy of Lung Cancer: EGFR Mutations and Response to EGFR InhibitorsPreprint

Haber, D. A., Bell, D. W., Sordella, R., Kwak, E. L., Godin-Heymann, N., Sharma, S. V., Lynch, T. J., & Settleman, J. E. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.043 · Cited by 112

Epidermal growth factor receptor mutations in lung adenocarcinoma

Siegelin, M. D., & Borczuk, A. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.147 · Cited by 234

Strategies for Overcoming Acquired Resistance to Epidermal Growth Factor Receptor–Targeted Therapies in Lung Cancer

Oxnard, G. R. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0254-ra · Cited by 21

Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms

Yamaoka, T., Ohba, M., & Ohmori, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112420 · Cited by 156